华东医药：2019年年度报告（英文版）.PDF

1、The 2019 Annul Report of Huadong Medicine Co.,Ltd.1 Huadong Medicine Co.,Ltd.The Annual Report 2019 April 2020 The 2019 Annul Report of Huadong Medicine Co.,Ltd.2 To the shareholders Dear Fellow Shareholders,2019 was a year where the pharmaceutical industry in China underwent significant structural

2、changes.It was also an incredibly important year for Huadong that we accelerated our transformation and took great strides toward a new era of growth.Look back on 2019,our employees had altogether accomplished outstanding results through commitment and relentless hard work.Overall,the company contin

3、ued to deliver solid overall performance and business results.Our companys financial results again reached new high record,with consolidated net profit increased by 24.08%to RMB 2.813billion.Zhongmei Huadong achieved annual sales revenue of more than RMB 10 billion for the first time,a historical mi

4、lestone.Zhongmei Huadong invested RMB1.055 billion in research and development(R&D),a 49.14%increase compared to prior year.We successfully established Zhongmei Huadong-centered a global R&D strategic collaboration ecosystem and completed R&D project evaluation and approval system.We made significan

5、t breakthroughs in research and innovation,where we saw TTP273,the worlds first oral small molecular GLP-1 agonist drug receiving regulatory approval to commence Phase I clinical trial,and other key R&D projects,including Mafatinib and Liraglutide,entering Phase III clinical trials.We also entered i

6、nto strategic collaborations with R2 and MediBeacon in the US and Kylane in Switzerland while obtained global commercialization rights to a number of innovative products,which enriched our product pipeline and drivers for future growth.In June 2019,we welcomed our new board of directors and successf